The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review

M. Monticelli, P. Zeppa, F. Zenga, R. Altieri, M. Mammi, L. Bertero, I. Castellano, P. Cassoni, A. Melcarne, Giuseppe La Rocca, Giovanni Sabatino, A. Ducati, D. Garbossa

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)

Abstract

Glioblastoma (GBM) is the most common glioma in adults, with incidence increasing by 3% per year. According to the World Health Organization Classification of Central Nervous System Tumors, GBM is considered a grade IV tumor due to its malignant behavior.The aim of this review is to summarize the main biological aspects of GBM. In particular, we focused our attention on those alterations which have been proven to have an impact on patients' outcome, mainly in terms of overall survival (OS), or on the tumor response to therapies. We have also analyzed the cellular biology and the interactions between GBM and the surrounding environment.
Lingua originaleEnglish
pagine (da-a)120-126
Numero di pagine7
RivistaClinical Neurology and Neurosurgery
Volume170
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • BRAE
  • Glioblastoma
  • High grade gliomas
  • IDH1
  • IDH2
  • MGMT
  • Molecular biology
  • TERT

Fingerprint

Entra nei temi di ricerca di 'The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review'. Insieme formano una fingerprint unica.

Cita questo